Furthermore, 45.0% (9/20) of the BRCA deleterious variants carriers were diagnosed with at least one triple negative breast cancer (TNBC) tumor, 15.0% (3/20) with at least one medullary carcinoma, 25.0% (5/20) with both tumors’ hormone receptor negative, 70.0% (14/20) both HER2 negative tumors and 20.0% (4/20) both TNBC, which was higher than that in non-carriers respectively. This evidence concerns the gene NR4A1 and neoplasm.